138 related articles for article (PubMed ID: 16323243)
1. A mutant human IgG molecule with only one C1q binding site can activate complement and induce lysis of target cells.
Michaelsen TE; Thommesen JE; Ihle O; Gregers TF; Sandin RH; Brekke OH; Sandlie I
Eur J Immunol; 2006 Jan; 36(1):129-38. PubMed ID: 16323243
[TBL] [Abstract][Full Text] [Related]
2. Structural difference in the complement activation site of human IgG1 and IgG3.
Michaelsen TE; Sandlie I; Bratlie DB; Sandin RH; Ihle O
Scand J Immunol; 2009 Dec; 70(6):553-64. PubMed ID: 19906198
[TBL] [Abstract][Full Text] [Related]
3. Effect of C2-associated carbohydrate structure on Ig effector function: studies with chimeric mouse-human IgG1 antibodies in glycosylation mutants of Chinese hamster ovary cells.
Wright A; Morrison SL
J Immunol; 1998 Apr; 160(7):3393-402. PubMed ID: 9531299
[TBL] [Abstract][Full Text] [Related]
4. The N-terminal end of the CH2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, Fc gamma RI and Fc gamma RIII binding.
Morgan A; Jones ND; Nesbitt AM; Chaplin L; Bodmer MW; Emtage JS
Immunology; 1995 Oct; 86(2):319-24. PubMed ID: 7490135
[TBL] [Abstract][Full Text] [Related]
5. Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region.
Tao MH; Morrison SL
J Immunol; 1989 Oct; 143(8):2595-601. PubMed ID: 2507634
[TBL] [Abstract][Full Text] [Related]
6. Lysine 322 in the human IgG3 C(H)2 domain is crucial for antibody dependent complement activation.
Thommesen JE; Michaelsen TE; Løset GÅ; Sandlie I; Brekke OH
Mol Immunol; 2000 Nov; 37(16):995-1004. PubMed ID: 11395138
[TBL] [Abstract][Full Text] [Related]
7. Activation of complement by an IgG molecule without a genetic hinge.
Brekke OH; Michaelsen TE; Sandin R; Sandlie I
Nature; 1993 Jun; 363(6430):628-30. PubMed ID: 8510754
[TBL] [Abstract][Full Text] [Related]
8. The binding site for C1q on IgG.
Duncan AR; Winter G
Nature; 1988 Apr; 332(6166):738-40. PubMed ID: 3258649
[TBL] [Abstract][Full Text] [Related]
9. Different glycosylation pattern of human IgG1 and IgG3 antibodies isolated from transiently as well as permanently transfected cell lines.
Vestrheim AC; Moen A; Egge-Jacobsen W; Bratlie DB; Michaelsen TE
Scand J Immunol; 2013 May; 77(5):419-28. PubMed ID: 23488770
[TBL] [Abstract][Full Text] [Related]
10. Addition of a mu-tailpiece to IgG results in polymeric antibodies with enhanced effector functions including complement-mediated cytolysis by IgG4.
Smith RI; Coloma MJ; Morrison SL
J Immunol; 1995 Mar; 154(5):2226-36. PubMed ID: 7868896
[TBL] [Abstract][Full Text] [Related]
11. [Binding and activation of the first component of human complement on artificial matrices].
Kozlov LV; Sizoĭ MN; Zinchenko AA; Ivanov AE; Zubov VP
Bioorg Khim; 1984 Dec; 10(12):1629-38. PubMed ID: 6529444
[TBL] [Abstract][Full Text] [Related]
12. Domain-switched mouse IgM/IgG2b hybrids indicate individual roles for C mu 2, C mu 3, and C mu 4 domains in the regulation of the interaction of IgM with complement C1q.
Chen FH; Arya SK; Rinfret A; Isenman DE; Shulman MJ; Painter RH
J Immunol; 1997 Oct; 159(7):3354-63. PubMed ID: 9317134
[TBL] [Abstract][Full Text] [Related]
13. Histidine-rich glycoprotein binds to human IgG and C1q and inhibits the formation of insoluble immune complexes.
Gorgani NN; Parish CR; Easterbrook Smith SB; Altin JG
Biochemistry; 1997 Jun; 36(22):6653-62. PubMed ID: 9184145
[TBL] [Abstract][Full Text] [Related]
14. Chimeric mouse human IgG3 antibodies with an IgG4-like hinge region induce complement-mediated lysis more efficiently than IgG3 with normal hinge.
Norderhaug L; Brekke OH; Bremnes B; Sandin R; Aase A; Michaelsen TE; Sandlie I
Eur J Immunol; 1991 Oct; 21(10):2379-84. PubMed ID: 1915551
[TBL] [Abstract][Full Text] [Related]
15. The relationship between the binding ability and the rate of activation of the complement component C1.
Folkerd EJ; Gardner B; Hughes-Jones NC
Immunology; 1980 Sep; 41(1):179-85. PubMed ID: 7429549
[TBL] [Abstract][Full Text] [Related]
16. C1q binding properties of monomer and polymer forms of mouse IgM mu-chain variants. Pro544Gly and Pro434Ala.
Taylor B; Wright JF; Arya S; Isenman DE; Shulman MJ; Painter RH
J Immunol; 1994 Dec; 153(11):5303-13. PubMed ID: 7963582
[TBL] [Abstract][Full Text] [Related]
17. Potential of Murine IgG1 and Human IgG4 to Inhibit the Classical Complement and Fcγ Receptor Activation Pathways.
Lilienthal GM; Rahmöller J; Petry J; Bartsch YC; Leliavski A; Ehlers M
Front Immunol; 2018; 9():958. PubMed ID: 29867943
[TBL] [Abstract][Full Text] [Related]
18. Effector functions of a mouse IgG that lacks the entire CH1 domain. C1q binding and complement fixation in the absence of antigen.
Mizutani R; Igarashi T; Tanaka T; Shimada I; Arata Y
J Immunol; 1993 Jan; 150(1):131-8. PubMed ID: 8417119
[TBL] [Abstract][Full Text] [Related]
19. Role of Ca2+ in the electrostatic stability and the functional activity of the globular domain of human C1q.
Roumenina LT; Kantardjiev AA; Atanasov BP; Waters P; Gadjeva M; Reid KB; Mantovani A; Kishore U; Kojouharova MS
Biochemistry; 2005 Nov; 44(43):14097-109. PubMed ID: 16245926
[TBL] [Abstract][Full Text] [Related]
20. Variable region domain exchange influences the functional properties of IgG.
Morrison SL; Porter SB; Trinh KR; Wims LA; Denham J; Oi VT
J Immunol; 1998 Mar; 160(6):2802-8. PubMed ID: 9510182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
